Your browser doesn't support javascript.
loading
Glioblastoma Neurovascular Progenitor Orchestrates Tumor Cell Type Diversity.
Fazzari, Elisa; Azizad, Daria J; Yu, Kwanha; Ge, Weihong; Li, Matthew X; Nano, Patricia R; Kan, Ryan L; Tum, Hong A; Tse, Christopher; Bayley, Nicholas A; Haka, Vjola; Cadet, Dimitri; Perryman, Travis; Soto, Jose A; Wick, Brittney; Raleigh, David R; Crouch, Elizabeth E; Patel, Kunal S; Liau, Linda M; Deneen, Benjamin; Nathanson, David A; Bhaduri, Aparna.
Afiliación
  • Fazzari E; Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, California, Los Angeles, CA, USA.
  • Azizad DJ; Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, California, Los Angeles, CA, USA.
  • Yu K; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
  • Ge W; Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, California, Los Angeles, CA, USA.
  • Li MX; Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, California, Los Angeles, CA, USA.
  • Nano PR; Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, California, Los Angeles, CA, USA.
  • Kan RL; Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, California, Los Angeles, CA, USA.
  • Tum HA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Tse C; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Bayley NA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Haka V; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Cadet D; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Perryman T; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, California, Los Angeles, CA, USA.
  • Soto JA; Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, California, Los Angeles, CA, USA.
  • Wick B; Genomics Institute, University of California Santa Cruz, Santa Cruz, CA, USA.
  • Raleigh DR; Department of Radiation Oncology, University of California San Francisco, San Francisco, California, USA.
  • Crouch EE; Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
  • Patel KS; Department of Pathology, University of California San Francisco, San Francisco, California, USA.
  • Liau LM; Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
  • Deneen B; The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA, USA.
  • Nathanson DA; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, California, Los Angeles, CA, USA.
  • Bhaduri A; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, California, Los Angeles, CA, USA.
bioRxiv ; 2024 Jul 24.
Article en En | MEDLINE | ID: mdl-39091877
ABSTRACT
Glioblastoma (GBM) is the deadliest form of primary brain tumor with limited treatment options. Recent studies have profiled GBM tumor heterogeneity, revealing numerous axes of variation that explain the molecular and spatial features of the tumor. Here, we seek to bridge descriptive characterization of GBM cell type heterogeneity with the functional role of individual populations within the tumor. Our lens leverages a gene program-centric meta-atlas of published transcriptomic studies to identify commonalities between diverse tumors and cell types in order to decipher the mechanisms that drive them. This approach led to the discovery of a tumor-derived stem cell population with mixed vascular and neural stem cell features, termed a neurovascular progenitor (NVP). Following in situ validation and molecular characterization of NVP cells in GBM patient samples, we characterized their function in vivo. Genetic depletion of NVP cells resulted in altered tumor cell composition, fewer cycling cells, and extended survival, underscoring their critical functional role. Clonal analysis of primary patient tumors in a human organoid tumor transplantation system demonstrated that the NVP has dual potency, generating both neuronal and vascular tumor cells. Although NVP cells comprise a small fraction of the tumor, these clonal analyses demonstrated that they strongly contribute to the total number of cycling cells in the tumor and generate a defined subset of the whole tumor. This study represents a paradigm by which cell type-specific interrogation of tumor populations can be used to study functional heterogeneity and therapeutically targetable vulnerabilities of GBM.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos